9.730CADMkt Cap: 635.63M CADP/E: —Last update: 2026-05-21
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug de…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap635.63M CAD
Enterprise Value492.67M CAD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-38.58M CAD
Revenue/Share—
Last Price9.730 CAD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees49
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.68
PEG—
EV/EBITDA-10.47
EV/Revenue—
P/S—
P/B4.05
EPS (TTM)-1.44
EPS (Forward)-1.27
52W Range
8.91073% of range10.04
52W High10.04 CAD
52W Low8.910 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-47.02%
ROA-44.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-28.55M CAD
CapEx (TTM)588.95K CAD
FCF Margin—
FCF Yield-2.88%
Net Debt-136.87M CAD
Net Debt/EBITDA2.91
Balance Sheet
Debt/Equity0.00
Current Ratio19.30
Quick Ratio18.95
Book Value/Sh2.402 CAD
Cash/Share2.247 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)16.00 CAD
Target Range14.00 CAD – 18.00 CAD
# Analysts2
Ownership
Shares Out.65.33M
Float46.73M
Insiders14.80%
Institutions46.59%
Short Interest
Short Ratio1.3d
Short % Float0.15%
Short % Out.0.11%
Shares Short70.64K
Short (prev mo.)82.11K
Technical
SMA 509.922 (-1.9%)
SMA 2009.381 (+3.7%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)96.36K
Avg Vol (10d)46.94K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—